Sanofi appoints Belén Garijo as new CEO
Sanofi has appointed Belén Garijo as CEO. Paul Hudson will leave on Feb. 17, 2026, with Olivier Charmeil serving as interim leader.
Sanofi has appointed Belén Garijo as CEO. Paul Hudson will leave on Feb. 17, 2026, with Olivier Charmeil serving as interim leader.
Engelhard has created a Transformation Office and appointed Ann-Katrin Frank as Chief Commercial Strategy Officer to steer strategic development.
Daiichi Sankyo has appointed Dr. Veronika Rozehnal as the new Head of the Translational Research Center Europe. She succeeds Dr. Jürgen Müller, who is retiring after nearly 30 years of research service.
After 22 years at Novo Nordisk, Thomas Rantzau steps down from the Board of Directors. His former alternate, Tanja Villumsen, assumes the role of employee representative with immediate effect.
Merck has appointed Benjamin Hein as a member of the Executive Board and CEO Electronics. The experienced executive will assume the role on May 1, 2026, succeeding Kai Beckmann.
As of January 1, 2026, Jonas Gehrling has joined the management team of Serviceplan Content Health. Together with Nadine van Maanen, he will lead the Berlin-based healthcare content agency.
Psyma+Exevia Health GmbH sets the course for the future: Heidi Lüttgens assumes management responsibility from Roland Herterich and Norbert Schell. The leadership transition combines continuity with new momentum for growth and innovation.
As of February 1, 2026, Alliance Healthcare Germany will bundle Sales and Marketing under one leadership. Florian Truckenbrodt will be responsible for both areas to further strengthen pharmacies in the market.
FUNKE strengthens its digital transformation and welcomes back Carsten Groß as Managing Director Digital Publishing. Starting February 2026, he will assume strategic responsibility for all digital growth areas within the regional media division.
Fresenius is restructuring its global communications: Katrin Kerner and Christian Wagner are taking over the Corporate Communications function on an interim basis. Both report directly to CEO Michael Sen.
Vetter announces the retirement of long-serving Managing Director Thomas Otto and presents a strategically planned succession model. He will remain with the company in an advisory capacity.
The Insurance Chamber is accelerating its marketing transformation and creating two new key roles for data-driven and digital growth. Annika Bäcker and Stefan Weller take on central leadership positions.
Scholz & Friends appoints Andreas Bilgeri as Managing Director of its Hamburg office. Starting December 1, 2025, he will take on strategic responsibility for key client mandates.
The Federal Assembly of the German Red Cross (GRC) has unanimously elected Hermann Gröhe as its new President. He succeeds Gerda Hasselfeldt and brings extensive experience from politics and the health sector.
Boehringer Ingelheim has appointed Harsha Deshmukh to its Executive Leadership Team. Starting February 1, 2026, he will lead IT and Global Business Services, strengthening the company’s digital transformation.
The Salus Group is realigning its structure: Effective January 1, 2026, Dr. Florian Block becomes the sole Managing Director of Herbaria Kräuterparadies GmbH, deepening the group's integration. After 25 years, Erwin Winkler moves to Bioland e. V. as Head of Market Management.
BAHN-BKK is reshaping its leadership: Christine Enenkel will become CEO on January 1, 2026, while Dominik Dany joins the executive board to support the fund’s strategic development.
Cochlear Germany introduces Dr. Delphine Lindel as a proven expert in strategic product management. The experienced healthcare specialist will immediately assume the position of Group Product Manager.
Dr. Hans-Peter Hubmann was unanimously confirmed as Chairman of DAPI and will continue to lead the institute for another four years.
As of November 1, Annika Hollmann has taken over as Head of Communications at the German Organ Transplantation Foundation (DSO), succeeding Birgit Blome, who is retiring.